SCHEMBL2278459

SCHEMBL2278459

O=C(Nc1cc(-c2ccc(F)cc2)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 7/20 0.71
ACLY P53396 2/20 0.65
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
PKM P14618 2/20 0.60
MAPT P10636 1/20 0.60
GRIK1 P39086 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
DHODH Q02127 1/20 0.60
HDAC1 Q13547 4/20 0.58
HDAC3 O15379 1/20 0.57
SUCNR1 Q9BXA5 1/20 0.55
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
KCNK3 O14649 1/20 0.52
KCNK9 Q9NPC2 1/20 0.52
SERPINE1 P05121 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2274953 0.96 ACLY (0.67) HDAC2ACLYMEN1KMT2APKM
SCHEMBL2275453 0.91 ACLY (0.76) HDAC2ACLYMEN1KMT2APKM
SCHEMBL2273961 0.90 ACLY (0.60) HDAC2ACLYMEN1KMT2APKM
SCHEMBL2272122 0.89 DHODH (0.57) HDAC2ACLYMEN1KMT2AMAPT
SCHEMBL2271280 0.89 ACLY (0.62) HDAC2ACLYMEN1KMT2APKM
SCHEMBL2273186 0.88 ACLY (0.68) HDAC2ACLYMEN1KMT2APKM
SCHEMBL2270222 0.88 DHODH (0.77) HDAC2ACLYMEN1KMT2APKM
SCHEMBL28860211 0.88 KMT2A (0.68) HDAC2ACLYMEN1KMT2APKM
SCHEMBL2272416 0.88 ACLY (0.64) HDAC2ACLYMEN1KMT2APKM
SCHEMBL2270598 0.87 ACLY (0.71) HDAC2ACLYMEN1KMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 HDAC2 276/4885ACLY 653/4885MEN1 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.